<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="2719">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 10, 2022</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03052712</url>
  </required_header>
  <id_info>
    <org_study_id>PI2015_843_0031</org_study_id>
    <nct_id>NCT03052712</nct_id>
  </id_info>
  <brief_title>Validation and Standardization of a Battery Evaluation of the Socio-emotional Functions in Various Neurological Pathologies</brief_title>
  <acronym>GREFEXII</acronym>
  <official_title>Validation and Standardization of a Battery Evaluation of the Socio-emotional Functions in Various Neurological Pathologies</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Centre Hospitalier Universitaire, Amiens</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Centre Hospitalier Universitaire, Amiens</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The role of disorders of socio-emotional processes in cerebral diseases such as Alzheimer's&#xD;
      disease, frontal temporal dementia, Parkinson's disease, Huntington's disease, traumatic&#xD;
      brain injury, stroke, focal lesions, has been recognized recently. Social cognition refers to&#xD;
      a large group of emotional and cognitive abilities regulating inter-individuals relationships&#xD;
      and it includes mainly theory of mind, emotional information processing and empathy. However,&#xD;
      assessment of socio-emotional processes is still largely based on experimental tests that are&#xD;
      not validated for clinical purpose. In addition their long duration of administration is not&#xD;
      adapted to clinical examination. Finally these tests have not been standardized and&#xD;
      normalized in French-speaking population.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    not enough patients&#xD;
  </why_stopped>
  <start_date type="Actual">September 9, 2016</start_date>
  <completion_date type="Actual">September 8, 2019</completion_date>
  <primary_completion_date type="Actual">September 8, 2019</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>tests of social cognition (questionnaire)</measure>
    <time_frame>3 years</time_frame>
    <description>standardize and validate in French-speaking population a comprehensive battery of tests of social cognition</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">44</enrollment>
  <condition>Alzheimer Disease</condition>
  <condition>Parkinson Disease</condition>
  <condition>Frontal Dementia</condition>
  <condition>Huntington Disease</condition>
  <condition>Traumatic Brain Injury</condition>
  <condition>Stroke</condition>
  <arm_group>
    <arm_group_label>Patients</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>battery of tests of social cognition</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>battery of tests of social cognition</description>
  </arm_group>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>social cognition</intervention_name>
    <description>battery of tests of social cognition</description>
    <arm_group_label>Control</arm_group_label>
    <arm_group_label>Patients</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Provision of signed and dated informed consent form (ICF)&#xD;
&#xD;
          2. Male or female, aged 20 to 80 years inclusive at the time of signing ICF&#xD;
&#xD;
          3. French-speaking&#xD;
&#xD;
          4. reliable informant&#xD;
&#xD;
             Controls:&#xD;
&#xD;
          5. derived from the general population and consenting to participate in the study&#xD;
&#xD;
             Patients:&#xD;
&#xD;
          6. MMS&gt;18&#xD;
&#xD;
          7. Patients followed for mild or major neurocognitive disorder related to :&#xD;
&#xD;
               -  Alzheimer's disease&#xD;
&#xD;
               -  Frontotemporal lobar degeneration&#xD;
&#xD;
               -  Lewy bodies disease&#xD;
&#xD;
               -  Parkinson's disease&#xD;
&#xD;
               -  Huntington's disease&#xD;
&#xD;
               -  Progressive supranuclear palsy&#xD;
&#xD;
               -  traumatic brain injury&#xD;
&#xD;
               -  stroke or cerebral anoxia&#xD;
&#xD;
               -  mixed diseases&#xD;
&#xD;
               -  focal cerebral diseases&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Illiteracy&#xD;
&#xD;
          2. mental retardation&#xD;
&#xD;
          3. visual or motor deficit preventing reading, drawing or writing (scores on the reading,&#xD;
             drawing or sentence writing subtests of the MMSE = 0)&#xD;
&#xD;
          4. hearing impairment interfering with understanding of instructions,&#xD;
&#xD;
          5. history of brain disease, including head injury with loss of consciousness lasting &gt;&#xD;
             15 minutes, stroke, coma or loss of consciousness lasting &gt; 15 minutes, followed for&#xD;
             sclerosis or other brain disease, brain radiation therapy, epilepsy currently&#xD;
             requiring treatment&#xD;
&#xD;
          6. history of psychiatric illness (schizophrenia or other psychosis) or ongoing&#xD;
             psychiatric illness (major depressive disorder or other condition) currently requiring&#xD;
             treatment or requiring a stay &gt; 2 days in a psychiatry unit or anxiety requiring more&#xD;
             than one medication at the present time&#xD;
&#xD;
          7. alcoholism (mean alcohol consumption &gt; 3 standard drinks/day or history of alcohol&#xD;
             withdrawal)&#xD;
&#xD;
          8. use of opiates or other illicit drugs during the previous 3 months or causing&#xD;
             withdrawal syndrome&#xD;
&#xD;
          9. ongoing antidepressant or antiepileptic treatment&#xD;
&#xD;
         10. anxiolytic or hypnotic treatment initiated or increased during the previous month&#xD;
&#xD;
         11. general anaesthesia during the previous 3 months&#xD;
&#xD;
         12. history of heart surgery with cardiopulmonary bypass&#xD;
&#xD;
         13. comorbidities affecting cognition (respiratory, renal, liver, heart failureâ€¦)&#xD;
&#xD;
         14. women of childbearing potential (defined as pre-menopausal, less than 2 years&#xD;
             postmenopausal, or not surgically sterile)&#xD;
&#xD;
         15. persons placed under judicial protection&#xD;
&#xD;
             Patients :&#xD;
&#xD;
         16. contraindication to MRI&#xD;
&#xD;
             Controls:&#xD;
&#xD;
         17. deficit on MMSE &lt;27&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Olivier GODEFROY, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>CHU Amiens</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>CHU Amiens</name>
      <address>
        <city>Amiens</city>
        <zip>80054</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>October 2019</verification_date>
  <study_first_submitted>February 7, 2017</study_first_submitted>
  <study_first_submitted_qc>February 10, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">February 14, 2017</study_first_posted>
  <last_update_submitted>October 17, 2019</last_update_submitted>
  <last_update_submitted_qc>October 17, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">October 21, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Disorders of socio-emotional</keyword>
  <keyword>Alzheimer</keyword>
  <keyword>frontal temporal dementia</keyword>
  <keyword>Parkinson</keyword>
  <keyword>Huntington</keyword>
  <keyword>traumatic brain injury</keyword>
  <keyword>stroke</keyword>
  <keyword>focal lesions</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Parkinson Disease</mesh_term>
    <mesh_term>Alzheimer Disease</mesh_term>
    <mesh_term>Dementia</mesh_term>
    <mesh_term>Brain Injuries</mesh_term>
    <mesh_term>Brain Injuries, Traumatic</mesh_term>
    <mesh_term>Huntington Disease</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

